71
Participants
Start Date
April 4, 2017
Primary Completion Date
April 5, 2019
Study Completion Date
March 5, 2020
UGN-101 instillations
Treatment with UGN-101 once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate complete response (CR) will be treated with UGN-101 once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Medical Center, New York
Montefiore Medical Center (Albert Einstein), The Bronx
Penn State College of Medicine, Hershey
Thomas Jefferson University Hospitals, Philadelphia
John Hopkins University, Baltimore
University of north carolina - chapel hill, Chapel Hill
Mayo Clinic Florida, Jacksonville
The Ohio State University Wexner Medical Center, Columbus
Indiana University School of Medicine, Indianapolis
University of Michigan Comprehensive Cancer Center, Ann Arbor
Hasharon Hospital (Rabin Medical Center), Petah Tikva
Sheba Medical Center, Ramat Gan
University of Minnesota, Minneapolis
Mayo Clinic health system, Rochester
Loyola University Medical Center, Department of Urology, Maywood
MD Anderson, Houston
Baylor College of Medicine, Houston
Mayo Clinic Hospital, Phoenix
Urology Center Las Vegas, Las Vegas
University of California, Los Angeles
Providence Medical Institute, Santa Monica
Loma Linda Cancer Center, Loma Linda
Seattle Cancer Care Alliance (University of Washington), Seattle
UroGen Pharma Ltd.
INDUSTRY